Laser-Heated Plasmonic Nanoparticles Safely Cause Localized Tumor Destruction
|
By LabMedica International staff writers Posted on 16 Aug 2016 |

Image: The experiments were carried out with nanoparticles of different sizes and structures. The first two of the series consisted of solid gold and the last consisted of a core of glass with a surface of gold. The beads were illuminated with near infrared light with wavelengths of 807 nanometers and 1064 nanometers. The most effective nanoparticle was the gold-plated glass bead (Photo courtesy of Kamilla Nørregaard, University of Copenhagen).
Cancer therapy based on plasmonic nanoparticles that homed to tumors, warmed on exposure to laser irradiation, and then selectively killed the cancer cells was optimized and shown to be effective in a mouse xenograft model.
Plasmonic nanoparticle-based photothermal cancer therapy is a promising new tool to inflict localized and irreversible damage to tumor tissue by heating, without harming surrounding healthy tissue.
Plasmonic resonance is a phenomenon that occurs when light is reflected off thin metal films, which may be used to measure interaction of biomolecules on the surface. An electron charge density wave arises at the surface of the film when light is reflected at the film under specific conditions. A fraction of the light energy incident at a defined angle can interact with the delocalized electrons in the metal film (plasmon) thus reducing the reflected light intensity. The angle of incidence at which this occurs is influenced by the refractive index close to the backside of the metal film, to which target molecules are immobilized. If ligands in a mobile phase running along a flow cell bind to the surface molecules, the local refractive index changes in proportion to the mass being immobilized. This can be monitored in real time by detecting changes in the intensity of the reflected light.
Investigators at the University of Copenhagen (Denmark) combined plasmonic resonance with nanoparticles made from gold or gold-covered glass as the basis for hyperthermic anticancer therapy. The effectiveness of the approach was assessed by PET (positron emission tomography).
The investigators described in the August 2, 2016, online edition of the journal Scientific Reports the quantification of heat generation and absorption cross-section of single irradiated nanoparticles using a temperature sensitive lipid-based assay that compared results to their theoretically predicted photo-absorption.
In vivo, the heat generation of irradiated nanoparticles was evaluated in human tumor xenografts in mice using 2-deoxy-2-[F-18]fluoro-D-glucose (18F-FDG) PET imaging. To validate the use of this platform, the investigators quantified the photothermal efficiency of near infrared resonant silica-gold nanoshells (AuNSs) and benchmarked this against the heating of colloidal spherical, solid gold nanoparticles (AuNPs). As expected, both in vitro and in vivo the heat generation of the resonant AuNSs performed better than the non-resonant AuNPs. Furthermore, the results showed that PET imaging could be reliably used to monitor early treatment response of photothermal treatment.
In the mouse study, 150 nanometer gold-covered glass nanoparticles were injected into tumors and then illuminated with near-infrared laser light, which penetrated through the tissue. In contrast to conventional radiation therapy, the near-infrared laser light caused no burn damage to the tissue that it passed through. Within an hour following the treatment, the investigators could detect cancer cell death on PET scans and determined that the effect continued for at least two days.
"The treatment involves injecting tiny nanoparticles directly into the cancer. Then you heat up the nanoparticles from outside using lasers. It is a strong interaction between the nanoparticles and the laser light, which causes the particles to heat up. What then happens is that the heated particles damage or kill the cancer cells," said senior author Dr. Lene Oddershede, professor of biophysics at the University of Copenhagen. "As physicists we have great expertise in the interaction between light and nanoparticles and we can very accurately measure the temperature of the heated nanoparticles. The effectiveness depends on the right combination between the structure and material of the particles, their physical size, and the wavelength of the light."
"Now we have proven that the method works. In the longer term, we would like the method to work by injecting the nanoparticles into the bloodstream, where they end up in the tumors that may have metastasized. With the PET scans we can see where the tumors are and irradiate them with lasers, while also effectively assessing how well the treatment has worked shortly after the irradiation. In addition, we will coat the particles with chemotherapy, which is released by the heat and which will also help kill the cancer cells," said Dr. Oddershede.
Related Links:
University of Copenhagen
Plasmonic nanoparticle-based photothermal cancer therapy is a promising new tool to inflict localized and irreversible damage to tumor tissue by heating, without harming surrounding healthy tissue.
Plasmonic resonance is a phenomenon that occurs when light is reflected off thin metal films, which may be used to measure interaction of biomolecules on the surface. An electron charge density wave arises at the surface of the film when light is reflected at the film under specific conditions. A fraction of the light energy incident at a defined angle can interact with the delocalized electrons in the metal film (plasmon) thus reducing the reflected light intensity. The angle of incidence at which this occurs is influenced by the refractive index close to the backside of the metal film, to which target molecules are immobilized. If ligands in a mobile phase running along a flow cell bind to the surface molecules, the local refractive index changes in proportion to the mass being immobilized. This can be monitored in real time by detecting changes in the intensity of the reflected light.
Investigators at the University of Copenhagen (Denmark) combined plasmonic resonance with nanoparticles made from gold or gold-covered glass as the basis for hyperthermic anticancer therapy. The effectiveness of the approach was assessed by PET (positron emission tomography).
The investigators described in the August 2, 2016, online edition of the journal Scientific Reports the quantification of heat generation and absorption cross-section of single irradiated nanoparticles using a temperature sensitive lipid-based assay that compared results to their theoretically predicted photo-absorption.
In vivo, the heat generation of irradiated nanoparticles was evaluated in human tumor xenografts in mice using 2-deoxy-2-[F-18]fluoro-D-glucose (18F-FDG) PET imaging. To validate the use of this platform, the investigators quantified the photothermal efficiency of near infrared resonant silica-gold nanoshells (AuNSs) and benchmarked this against the heating of colloidal spherical, solid gold nanoparticles (AuNPs). As expected, both in vitro and in vivo the heat generation of the resonant AuNSs performed better than the non-resonant AuNPs. Furthermore, the results showed that PET imaging could be reliably used to monitor early treatment response of photothermal treatment.
In the mouse study, 150 nanometer gold-covered glass nanoparticles were injected into tumors and then illuminated with near-infrared laser light, which penetrated through the tissue. In contrast to conventional radiation therapy, the near-infrared laser light caused no burn damage to the tissue that it passed through. Within an hour following the treatment, the investigators could detect cancer cell death on PET scans and determined that the effect continued for at least two days.
"The treatment involves injecting tiny nanoparticles directly into the cancer. Then you heat up the nanoparticles from outside using lasers. It is a strong interaction between the nanoparticles and the laser light, which causes the particles to heat up. What then happens is that the heated particles damage or kill the cancer cells," said senior author Dr. Lene Oddershede, professor of biophysics at the University of Copenhagen. "As physicists we have great expertise in the interaction between light and nanoparticles and we can very accurately measure the temperature of the heated nanoparticles. The effectiveness depends on the right combination between the structure and material of the particles, their physical size, and the wavelength of the light."
"Now we have proven that the method works. In the longer term, we would like the method to work by injecting the nanoparticles into the bloodstream, where they end up in the tumors that may have metastasized. With the PET scans we can see where the tumors are and irradiate them with lasers, while also effectively assessing how well the treatment has worked shortly after the irradiation. In addition, we will coat the particles with chemotherapy, which is released by the heat and which will also help kill the cancer cells," said Dr. Oddershede.
Related Links:
University of Copenhagen
Latest BioResearch News
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
Channels
Clinical Chemistry
view channel
Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreMolecular Diagnostics
view channel
New Library Normalization and Amplification Tools Support Oncology Sequencing
High-throughput next-generation sequencing (NGS) laboratories continue to grapple with uneven library pooling and amplification artifacts that can degrade variant calling accuracy and increase reruns.... Read more
Statistical Method Improves Detection of Low-Level Cancer DNA in Blood Samples
Blood-based assays are increasingly used to detect and monitor cancer, but many require relatively high fractions of circulating tumor DNA, limiting their utility when disease burden is low.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more








